Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 7, 2005. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On November 3, 2005, the Administrators notified the company of an increase in the notional allocation of Ordinary Share ADRs at a price of $52.43 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Date: November 3, 2005.
- Share Price: $52.43 per share for the notional allocation increase.
- Instrument: GSK Ordinary Share ADRs within the US Retirement Savings Plan.
- Participants: The notification lists specific allocations for nine individuals, including Dr. J P Garnier (34 shares), Mr. D Phelan (108 shares), and Dr. R Greig (48 shares).
- Signatory: Simon Bicknell, Company Secretary.